Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.18 USD | -0.84% | -1.67% | +0.85% |
May. 13 | HC Wainwright Adjusts Price Target on Clearside Biomedical to $5 From $6, Keeps Buy Rating | MT |
May. 09 | Transcript : Clearside Biomedical, Inc., Q1 2024 Earnings Call, May 09, 2024 |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+0.85% | 88.18M | |
+16.42% | 122B | |
+19.02% | 113B | |
+3.52% | 22.66B | |
-11.63% | 16.68B | |
-16.50% | 16.61B | |
-39.57% | 16.92B | |
+2.68% | 13.62B | |
+21.16% | 11.04B | |
+108.78% | 10.43B |
- Stock Market
- Equities
- CLSD Stock
- News Clearside Biomedical, Inc.
- Clearside Biomedical Says Trial Showed Favorable Safety Profile for Macular Degeneration Treatment